[go: up one dir, main page]

CU24556B1 - Anticuerpos anti-basigin humanizados - Google Patents

Anticuerpos anti-basigin humanizados

Info

Publication number
CU24556B1
CU24556B1 CU2018000129A CU20180129A CU24556B1 CU 24556 B1 CU24556 B1 CU 24556B1 CU 2018000129 A CU2018000129 A CU 2018000129A CU 20180129 A CU20180129 A CU 20180129A CU 24556 B1 CU24556 B1 CU 24556B1
Authority
CU
Cuba
Prior art keywords
humanized anti
basigin
basigin antibodies
antibodies
antigen
Prior art date
Application number
CU2018000129A
Other languages
English (en)
Other versions
CU20180129A7 (es
Inventor
Huijie Bian
Zhinan Chen
Wan Huang
Jianli Jiang
Mengyao Zhang
Yang Zhang
Zheng Zhang
Ping Zhu
Original Assignee
Fourth Military Medical Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fourth Military Medical Univ filed Critical Fourth Military Medical Univ
Publication of CU20180129A7 publication Critical patent/CU20180129A7/es
Publication of CU24556B1 publication Critical patent/CU24556B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente divulgación proporciona un anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, también proporciona una secuencia de ácidos nucleicos que codifica el anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo.</p>
CU2018000129A 2016-04-29 2017-05-02 Anticuerpos anti-basigin humanizados CU24556B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610285139.4A CN105820250B (zh) 2016-04-29 2016-04-29 一种抗basigin人源化抗体及其应用
PCT/CN2017/082713 WO2017186182A1 (en) 2016-04-29 2017-05-02 Humanized anti-basigin antibodies and the use thereof

Publications (2)

Publication Number Publication Date
CU20180129A7 CU20180129A7 (es) 2019-06-04
CU24556B1 true CU24556B1 (es) 2021-12-08

Family

ID=56528099

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000129A CU24556B1 (es) 2016-04-29 2017-05-02 Anticuerpos anti-basigin humanizados

Country Status (26)

Country Link
US (2) US12240901B2 (es)
EP (1) EP3448892A4 (es)
JP (2) JP7099709B2 (es)
KR (1) KR102369118B1 (es)
CN (2) CN105820250B (es)
AU (1) AU2017255888B2 (es)
BR (1) BR112018072140A2 (es)
CA (1) CA3022308A1 (es)
CL (1) CL2018003072A1 (es)
CO (1) CO2018011663A2 (es)
CR (1) CR20180515A (es)
CU (1) CU24556B1 (es)
DO (1) DOP2018000234A (es)
EC (1) ECSP18084153A (es)
IL (1) IL262588B2 (es)
MA (1) MA44777A (es)
MX (1) MX2018013176A (es)
MY (1) MY196874A (es)
NI (1) NI201800113A (es)
PE (1) PE20190415A1 (es)
PH (1) PH12018502293B1 (es)
RU (1) RU2755150C2 (es)
SG (1) SG11201809473QA (es)
TN (1) TN2018000358A1 (es)
WO (1) WO2017186182A1 (es)
ZA (1) ZA201807132B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
CN111690062B (zh) * 2019-03-14 2024-07-16 复旦大学 针对恶性疟PfRh5靶点的全人源单克隆抗体及应用
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
CN111420048B (zh) * 2020-03-11 2023-09-19 中国人民解放军第四军医大学 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN113549152B (zh) * 2021-07-22 2023-06-20 中国人民解放军空军军医大学 一种抗basigin人源化抗体及其应用
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
CN119775410B (zh) * 2025-03-11 2025-04-29 成都大熊猫繁育研究基地 一种抗大熊猫vegfa单克隆抗体、杂交瘤细胞株及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
NZ524523A (en) * 2000-08-03 2006-02-24 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals
US20050214302A1 (en) * 2004-03-25 2005-09-29 Marian Nakada Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
DK2087002T3 (da) * 2006-10-27 2014-10-27 Lpath Inc Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
WO2008144757A1 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Novel rabbit antibody humanization methods and humanized rabbit antibodies
CN101809162B (zh) * 2007-09-28 2013-06-05 中外制药株式会社 血浆中动力学被改善的磷脂酰肌醇蛋白聚糖3抗体
CN101550416B (zh) * 2008-03-18 2012-01-25 陈志南 人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用
US8007808B2 (en) * 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
EP2303325A4 (en) 2008-05-23 2012-09-19 Uti Limited Partnership INHIBITION OF EMMPRIN TO TREAT MULTIPLE SCLEROSIS
WO2010087743A2 (en) * 2008-12-30 2010-08-05 Cellartis Ab The use of a protein in stem cell and cancer applications
EP2997974B1 (en) * 2009-06-19 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of neurodegenerative disorders
WO2011056894A2 (en) 2009-11-03 2011-05-12 Jensen Michael C TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
HUE044179T2 (hu) * 2009-12-10 2019-10-28 Hoffmann La Roche Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása
US20110223176A1 (en) * 2010-03-11 2011-09-15 Abbott Laboratories Basigin binding proteins
CN104086654B (zh) * 2014-07-04 2016-06-08 中国人民解放军第四军医大学 人源化修饰型抗CD147嵌合抗体HcHAb18及其应用
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
CA3055574A1 (en) * 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof

Also Published As

Publication number Publication date
ECSP18084153A (es) 2019-03-29
RU2755150C2 (ru) 2021-09-13
IL262588B1 (en) 2024-07-01
EP3448892A4 (en) 2019-10-16
JP2022084832A (ja) 2022-06-07
TN2018000358A1 (en) 2020-06-15
JP7099709B2 (ja) 2022-07-12
RU2018138053A3 (es) 2020-08-21
RU2018138053A (ru) 2020-05-29
CN105820250B (zh) 2019-04-30
BR112018072140A2 (pt) 2019-02-12
SG11201809473QA (en) 2018-11-29
IL262588A (en) 2018-12-31
MX2018013176A (es) 2019-06-24
MY196874A (en) 2023-05-08
US20190270809A1 (en) 2019-09-05
PE20190415A1 (es) 2019-03-19
WO2017186182A1 (en) 2017-11-02
CR20180515A (es) 2019-05-15
ZA201807132B (en) 2021-05-26
CA3022308A1 (en) 2017-11-02
PH12018502293B1 (en) 2024-02-02
NI201800113A (es) 2020-01-06
EP3448892A1 (en) 2019-03-06
CO2018011663A2 (es) 2019-02-08
KR102369118B1 (ko) 2022-03-03
AU2017255888A1 (en) 2018-11-22
CN109476760B (zh) 2021-11-12
KR20190020660A (ko) 2019-03-04
MA44777A (fr) 2019-03-06
CL2018003072A1 (es) 2019-05-31
CN105820250A (zh) 2016-08-03
JP2019521648A (ja) 2019-08-08
DOP2018000234A (es) 2018-10-31
PH12018502293A1 (en) 2019-07-08
IL262588B2 (en) 2024-11-01
AU2017255888B2 (en) 2021-01-07
CU20180129A7 (es) 2019-06-04
US12240901B2 (en) 2025-03-04
CN109476760A (zh) 2019-03-15
US20250243273A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
CU24556B1 (es) Anticuerpos anti-basigin humanizados
CL2021000630A1 (es) Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585)
MX2019008146A (es) Virus alterado.
CR20170026A (es) Anticuerpos anti-tau humanizados
DK3402820T3 (da) Humaniserede, muse- eller kimære anti-cd47-monoklonale antistoffer
CU24568B1 (es) Anticuerpo inhibidor de masp-3
MX380937B (es) Anticuerpos dobles especificos.
CO2019002369A2 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
MX2017015042A (es) Anticuerpos cd123 y conjugados de los mismos.
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
EA202092435A2 (ru) Моноклональные антитела против bcma
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
CO2019002370A2 (es) Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
CL2016001979A1 (es) Métodos de tratamiento de enfermedad de alzheimer.
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
ES3052837T3 (en) Humanized anti-tau(ps422) antibodies and methods of use
ZA201703510B (en) Antibodies, uses &amp; methods
CL2017002614A1 (es) Método para la purificación de proteínas
PE20230381A1 (es) Proteina de union a rgma
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
CO2018010286A2 (es) Método para la purificación de proteínas
MX2016010995A (es) Novedoso anticuerpo anti-presepsina.